Friday, November 13, 2026

Crude Oil Futures Went Up By Over 2% In The Last 5 Sessions

Automated market report from our archive (2020–2024), published before source-traceability. How we work

Crude Oil Futures Went Up By Over 2% In The Last 5 Sessions

(VIANEWS) - Crude Oil (CL) has been up by 2.87% for the last 5 sessions. At 20:50 EST on Friday, 21 June, Crude Oil (CL) is $80.59.

Volume

Today's last reported volume for Crude Oil is 271228, 99.99% below its average volume of 12454312162.96.

Volatility

Crude Oil's last week, last month's, and last quarter's current intraday variation average was 0.83%, 0.47%, and 1.51%, respectively.

Crude Oil's highest amplitude of average volatility was 1.44% (last week), 1.39% (last month), and 1.51% (last quarter), respectively.

Commodity Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Crude Oil's commodity is considered to be overbought (>=80).

Previous days news about Crude Oil (CL)

  • Crude oil climbs again, WTI Marches toward $82 after EIA barrel count declines. According to FXStreet on Thursday, 20 June, "The Energy Information Administration (EIA) reported an unexpected decline in US Crude Oil Stocks Change for the week ended June 14. ", "West Texas Intermediate (WTI) US Crude Oil inched into fresh highs on Thursday, clipping $81.40 and continuing its march towards the $82.00 handle. "

More news about Crude Oil (CL).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com